Osimertinib plus savolitinib ‘new global standard of care’ for EGFR-mutant NSCLC
AstraZeneca's osimertinib plus Pfizer's savolitinib significantly improved progression-free and overall survival in EGFR-mutant NSCLC with MET overexpression/amplification, per phase 3 trial data presented at ESMO Congress. The combination reduced risk of progression/death by 45% vs. chemotherapy, with median OS of 17.8 months vs. 12.9 months. Researchers propose it as a new standard of care for this patient population.
How this was made
The 30-second read
Why it matters
The data could trigger label expansion discussions, partnership deals, and boost investor sentiment for both AstraZeneca and Pfizer.
Market read
First‑report trial results with clear survival benefit, likely to move biotech and pharma stocks.
What to watch
Potential safety concerns or pricing pressures in key markets could temper the rally.
Background
The SAFFRON phase 3 trial presented at ESMO shows a 45% risk reduction and longer overall survival for the osimertinib‑savolitinib combo.
Ticker impact
Phase 3 trial shows osimertinib plus savolitinib improves survival in EGFR‑mutant NSCLC, a drug combo owned by AstraZeneca.
upward pressure as investors price in potential label expansion and future sales.
New, material efficacy data for a marketed drug (Tagrisso) combined with a partner's MET inhibitor suggests a new indication, which can drive revenue growth.
Savolitinib, a MET‑TKI developed by Pfizer, is part of the trial showing significant benefit when combined with AstraZeneca's osimertinib.
upward pressure as the market anticipates potential co‑development or licensing revenue.
The data creates a clear path for Pfizer to monetize savolitinib in a high‑need NSCLC segment.
Market effects
Strengthens the broader oncology/targeted‑therapy sector, supporting other EGFR/MET drug developers.
May benefit US biotech indices and European pharma stocks with similar pipelines.
Sets a new standard of care globally for EGFR‑mutant NSCLC, influencing treatment guidelines.
Counterpoint
If regulatory hurdles delay approval or competition intensifies, the upside may be limited.
Key entities
- companyAstraZeneca
Owner of osimertinib (Tagrisso) and co‑developer of the combination therapy.
- companyPfizer
Developer of savolitinib (Sutent) used in the trial.
